ABT News 39.99 10/17/2014 04:22:12 Abbott Laboratories (ABT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbott Laboratories (ABT) 39.99 $ABT

Abbott Acknowledged by Science Magazine as a Top Employer
PR Newswire - Thu Oct 16, 3:30PM CDT
Abbott (NYSE: ABT) today was named one of the Top 20 Employers by the journal Science. The global healthcare company ranked No. 12 overall, receiving high marks for treating employees with respect and social responsibility.
ABT: 39.99 (-0.02)

How to Profit From October's Volatile Market
at The Street - Thu Oct 16, 11:23AM CDT
Volatility is back with a vengeance this month -- but that doesn't have to be a bad thing. Here's how to profit from the bigger swings in stock prices.
RAI: 57.07 (-0.27), ABT: 39.99 (-0.02), VXX: 40.33 (+0.92), DLR: 63.02 (-0.63)

Look for Shares of Abbott Laboratories to Potentially Rebound after Yesterday's 2.56% Sell Off
Comtex SmarTrend(R) - Wed Oct 15, 4:54PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.36 to a high of $40.53. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $40.87 on volume of 9.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 39.99 (-0.02)

Shire Falls, AbbVie Questioned On Buyout Backtrack
at Investor's Business Daily - Wed Oct 15, 12:11PM CDT
Shares of specialty drugmaker Shire plummeted 23% on the stock market today after word got out late Tuesday that big pharma AbbVie is reconsidering its $55 billion buyout of the company. Shire (SHPG) confirmed the reports Wednesday morning with a...
ABT: 39.99 (-0.02), AZN: 67.56 (-0.85), PFE: 27.70 (-0.49), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), MYL: 48.77 (+1.39), ABBV: 52.90 (-1.73)

China Interventional Cardiovascular Device Industry Report 2014-2017
M2 - Wed Oct 15, 8:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vk2z4c/china) has announced the addition of the "China Interventional Cardiovascular Device Industry Report,2014-2017" report to their offering. The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion. At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan. Affected by the implementation of Regulations on the Centralized Procurement of High-value Medical Consumables, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017. China Interventional Cardiovascular Device Industry Report, 2014-2017 focuses on the following: - Status quo of China interventional cardiovascular device industry, including overview, market demand, import & export, competitive landscape and entry barriers; - Development environment of China interventional cardiovascular device industry, embracing macro environment, policy climate and upstream & downstream sectors; - Status quo, competitive landscape, etc. of China interventional cardiovascular device market segments, covering coronary stent, balloon catheter, catheter, guidewire, sheath group and auxiliary devices; - Operation, interventional cardiovascular device business, etc. of 6 foreign and 12 Chinese interventional cardiovascular device companies. Key Topics Covered: 1. Overview of Interventional Cardiovascular Device Industry 2. Status Quo of China Interventional Cardiovascular Device Industry 3. Development Environment of China Interventional Cardiovascular Device Industry 4. Market Segments of China Interventional Cardiovascular Device Industry 5. Foreign Companies in China 6. Major Domestic Companies 7 Forecast and Outlook Companies Mentioned - Abbott Laboratories - AmsinoMed Medical Device - B. Braun - Boston Scientific - Dalian Yinyi - Demax Medical - JW Medical - Johnson & Johnson - Lepu Medical - Lifetech Scientific - Medtronic - MicroPort - Neich Medical (Shenzhen) - SCW Medicath - Sino Medical - Starway Medical - Synexmed - Terumo For more information visit http://www.researchandmarkets.com/research/vk2z4c/china
BSX: 11.45 (+0.01), JNJ: 96.78 (-1.43), ABT: 39.99 (-0.02), MDT: 61.81 (-0.44)

Global Partial Seizure Clinical Trials Review, H2, 2014
M2 - Wed Oct 15, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8gwn27/partial_seizure) has announced the addition of the "Partial Seizure Global Clinical Trials Review, H2, 2014" report to their offering. Partial Seizure Global Clinical Trials Review, H2, 2014 provides data on the Partial Seizure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Partial Seizure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Partial Seizure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Partial Seizure Therapeutics Clinical Trials - UCB S.A. - Pfizer Inc. - Eisai Co., Ltd. - Novartis AG - Johnson & Johnson - GlaxoSmithKline plc - Bial - Portela & Ca, S.A. - SK Holdings Co., Ltd. - Upsher-Smith Laboratories, Inc. - Abbott Laboratories - National Institute of Neurological Disorders and Stroke - Emory University - Oregon Health & Science University - Kyoto University - National Center for Complementary and Alternative Medicine - Hadassah Medical Organization - University of Pennsylvania - Lawson Health Research Institute - Massachusetts General Hospital - University of California, Davis For more information visit http://www.researchandmarkets.com/research/8g...al_seizure
JNJ: 96.78 (-1.43), ABT: 39.99 (-0.02), PFE: 27.70 (-0.49), GSK: 42.88 (-0.25), NVS: 85.02 (-1.20)

Affordable Housing Project, Lawsuit Settlement, Drug Review, and Earnings Release Schedules - Research Reports on UnitedHealth, Bristol-Myers, Boston Scientific, Abbott and Illumina
PR Newswire - Tue Oct 14, 7:55AM CDT
Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7151-100free.
BSX: 11.45 (+0.01), ABT: 39.99 (-0.02), UNH: 85.39 (+3.23), ILMN: 160.23 (+6.64), BMY: 49.22 (+0.26)

Global Low-Calorie Food Market Outlook 2019 - Key Analysis of the $7.4 Billion Industry
M2 - Tue Oct 14, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7xnwf/lowcalorie_food) has announced the addition of the "Low-calorie Food Market - Global Forecast, Share, Size, Growth and Industry Analysis, 2014 - 2019" report to their offering. The global low-calorie food market was USD 7,418.6 million in 2013. Sucralose is expected to be the fastest growing segment, likely to register a strong growth in the future. Usage of low-calorie food products in the beverages sector is forecasted to increase by 5.9% CAGR from 2014 to 2019. Based on application the low calorie food market is broadly classified under, food, beverages, healthcare, tabletop and others. On the basis product segment, Aspartame, Sucralose, Stevia, Saccharin and Cyclamate are the broad categories. Aspartame is one of the most widely used artificial sweeteners. In the recent scenario, sucralose is gaining more popularity than aspartame. Growing consumer preferences for all-natural products have created a huge demand for stevia. Due to its growing popularity as a 100% natural sweetener, stevia is giving tough competition to other high-intensity sweeteners such as aspartame, saccharin and sucralose. The U.S. is the largest market for low calorie food, followed by the European countries. The developing nations in the Asia-Pacific region are expected to show high growth in the next five years. Some of the major companies operating in the market are PepsiCo Inc., The Coca-Cola Company, Groupe Danone, Bernard Food Industries, Inc., Nestle S.A., Ajinomoto Co., Inc., McNeil Nutritionals, LLC and Cargill, Incorporated. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Low-calorie Food Market - Industry Overview Chapter 4 Low-calorie Food Market- Product Segment Analysis Chapter 5 Low-calorie Food Market: by Application Chapter 6 Low-calorie Food Market- Regional Analysis Chapter 7 Competitive Landscape Chapter 8 Company Profiles - Abbott Laboratories - Ajinomoto Co., Inc. - Bernard Food Industries, Inc. - Cargill, Incorporated - Dr Pepper Snapple Group Inc. - Groupe Danone - McNeil Nutritionals LLC - Nestle SA - PepsiCo, Inc. - The Coca-Cola Company - Zydus Wellness Ltd. For more information visit http://www.researchandmarkets.com/research/t7...lorie_food
ABT: 39.99 (-0.02), PEP: 90.79 (-0.98)

InvestorsObserver releases comments on Google, Wells Fargo, eBay, Abbott Labs, and Netflix
PR Newswire - Mon Oct 13, 8:31AM CDT
InvestorsObserver.com releases its Stocks To Watch guide.
NFLX: 361.70 (-86.89), ABT: 39.99 (-0.02), EBAY: 47.88 (-2.36), WFC: 48.13 (+0.28), GOOGL: 536.92 (-3.81)

3 Big Stocks to Buy in a Volatile Market
at The Street - Fri Oct 10, 12:34PM CDT
This week's volatile selling spree could be just the beginning.
RAI: 57.07 (-0.27), ABT: 39.99 (-0.02), DLR: 63.02 (-0.63)

Abbott Celebrates the Power of Health and Achievement as First-Ever Title Sponsor of World Marathon Majors
PR Newswire - Fri Oct 10, 9:36AM CDT
Abbott (NYSE: ABT) and the World Marathon Majors announced a new partnership with Abbott becoming the race series' first-ever title sponsor. The series - comprising six of the largest and most renowned marathons in the world: Tokyo, Boston, Virgin Money London, BMW BERLIN, Bank of America Chicago and TCS New York City Marathon - will be renamed the Abbott World Marathon Majors starting in 2015.
ABT: 39.99 (-0.02)

Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 10, 7:50AM CDT
Amgen 's Enbrel hasn't been able to keep pace with AbbVie 's Humira, managing $4.2 billion in U.S. sales last year compared to Humira's $5.2 billion. So what's Amgen to do? Make a copycat of Humira, of course. You're not seeing double. ...
ABT: 39.99 (-0.02), AMGN: 130.45 (-0.45), ABBV: 52.90 (-1.73)

How Endo International's $2.6B Deal for Auxilium Benefits Shareholders
at The Street - Thu Oct 09, 12:53PM CDT
With this deal for Auxilium, Endo has just turned itself into a top-tier global specialty health care leader.
ENDP: 60.59 (+0.40), ABT: 39.99 (-0.02), QLTI: 3.99 (+0.03), ACT: 222.07 (+4.83), AUXL: 30.35 (-0.06)

Global Biological Drugs Market Outlook 2020
M2 - Thu Oct 09, 2:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sv5tsf/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb) and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. On the other hand, high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market. Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc. and Biogen Idec. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/sv...ical_drugs
BIIB: 302.74 (-2.95), ABT: 39.99 (-0.02), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), AMGN: 130.45 (-0.45), LLY: 61.90 (-0.97), GSK: 42.88 (-0.25), BMY: 49.22 (+0.26), NVS: 85.02 (-1.20)

New Frontiers in the US Clinical Chemistry and Immunodiagnostic Markets 2014: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Wed Oct 08, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/smq5b7/new_frontiers_in) has announced the addition of the "New Frontiers in the US Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape" report to their offering. New Frontiers in the U.S. Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape; is Venture Planning Group's new study of the major business opportunities emerging in the U.S. clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the U.S. market; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables. U.S. Market Overview - Estimates of facilities performing clinical chemistry and immunodiagnostic tests. - Test volume and sales projections. Strategic Recommendations - New product development opportunities with significant market appeal. - Alternative market penetration strategies. - Potential market entry barriers and risks. Market Segmentation Analysis - Comprehensive review of the market dynamics, trends, structure, size, growth, and key suppliers. - Test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, by market segment:? Hospitals ? Commercial/Private Laboratories ? Physician Offices/Group Practices The companies analyzed in the report include: - Abbott Laboratories - AdnaGen - Agilent Technologies - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio/Innogenetics - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/sm...ontiers_in
ABT: 39.99 (-0.02), A: 51.71 (-0.08), DGX: 57.93 (+0.22), DHR: 74.19 (+2.21)

Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.61 (+0.06), ABT: 39.99 (-0.02), BMY: 49.22 (+0.26)

ISRG - Stunning Visualizations Pinpoint Hidden Risk
OptionVol - Mon Oct 06, 5:05PM CDT
This visualization is provided by: Capital Market Laboratories: Get Notified When CML Light Goes Live ISRG is trading $486.58, up 2.4% with IV30™ up 8.4%. The Symbol Summary is included below. Provided by Livevol Conclusion Relativ...
1 Comment
ISRG: 456.51 (-3.63), ABT: 39.99 (-0.02), BCR: 144.77 (-3.02), MDT: 61.81 (-0.44)

After Yesterday's Rally of 1.36% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Oct 06, 4:00PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $41.99 to a high of $42.47. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $42.06 on volume of 6.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 39.99 (-0.02)

Abbott Laboratories (ABT) Approaches New Upside Target of $42.23
Comtex SmarTrend(R) - Mon Oct 06, 11:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $41.64 today and have reached the first resistance level of $42.01. Should the shares continue to rise, the resistance pivots of $42.23 and $42.82 will be of interest.
ABT: 39.99 (-0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 94

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 142

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 154

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 141

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 133

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 55

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet

Updated Category News Views 44

Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 25

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 65

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading

Top 5 Most Recently Viewed Articles

Rogers Communications Adjusts Revenue Forecast After Sports Deal

Updated Category News Views 203

Rogers Communications Expands Outlook Following Sports Acquisition Rogers Communications, Inc. (NYSE: RCI) has made headlines after raising its full-year service revenue guidance following a solid earnings performance. Despite a slight decline in stock value, investors reacted positively to the company's updated expectations after their second-quarter financial report....

Continue Reading
Tata Communications Expands AI Capabilities with New Acquisition

Updated Category News Views 188

Tata Communications Enhances AI Capabilities Tata Communications, a prominent player in the global communications technology landscape, has recently taken a significant step in advancing its AI capabilities. The company announced its acquisition of a 51% stake in Commotion Inc., an innovative AI-native Enterprise SaaS platform. This acquisition highlights Tata...

Continue Reading
Taboola to Announce Q3 2024 Earnings: Conference Call Details

Updated Category News Views 152

Taboola Prepares for Third Quarter 2024 Financial Announcement Taboola, renowned for its dynamic recommendation platform, is making headlines as it gears up to release its financial results for the third quarter of 2024. This exciting event is scheduled for a Thursday morning before the market opens, paving the way for insights into the company's performance. Date and...

Continue Reading
Aker Horizons ASA Holds Key Extraordinary General Meeting

Updated Category News Views 126

Aker Horizons ASA Holds Key Extraordinary General Meeting In a significant step for Aker Horizons ASA, the company's extraordinary general meeting was successfully conducted. The meeting, held digitally, emphasized the importance of engaging stakeholders through innovative online participation. This format makes it easier for shareholders to be involved, regardless of...

Continue Reading
Energizer® Portable Power Expands European Availability Now

Updated Category News Views 147

Energizer® Portable Power Expands European Availability Energizer, a name synonymous with reliable power solutions, has taken a bold step forward with the expansion of its portable power ecosystem across Europe. This strategic move by TennRich International Corp. signals a commitment to enhancing modern lifestyles, perfectly aligning with the needs of consumers at home,...

Continue Reading